Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

5′-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 15: 2429–2440.

    Article  Google Scholar 

  2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label, phase III study. Lancet Oncol 2009; 10: 223–232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Feanux P, Ades L . Review of azacitidine trials in intermediate-2 and high-risk myelodysplastic syndromes. Leuk Res 2009; 33: S7–S11.

    Article  Google Scholar 

  4. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors of response and overall survival in 282 higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403–411.

    Article  CAS  PubMed  Google Scholar 

  5. Nucifora G . The EVI-1 gene in myeloid leukemia. Leukemia 1997; 11: 2022–2031.

    Article  CAS  PubMed  Google Scholar 

  6. Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N et al. EVI-1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer 2006; 45: 349–356.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Breccia.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breccia, M., Cannella, L., Santopietro, M. et al. 5′-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3. Leukemia 25, 736–737 (2011). https://doi.org/10.1038/leu.2011.6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.6

Search

Quick links